Harmony Biosciences stock: HC Wainwright trims EPS outlook
Published on 11/17/2026 at 00:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst trims near-term outlook
- HC Wainwright lowered its full-year EPS forecast while retaining a Buy rating and a USD 55 price target.
- Third-quarter revenue rose to USD 268.92 million, but EPS missed the analyst estimate.
- Harmony continues to build its rare-neurology pipeline around WAKIX and BP-205.
HC Wainwright lowered its full-year earnings-per-share forecast for Harmony Biosciences to USD 3.37 from USD 3.52 in a research note issued on November 12, according to MarketBeat. The analyst retained a Buy rating and a USD 55 price target.
Lower forecast after earnings miss
The revision followed Harmony's third-quarter report on November 4. The company posted diluted EPS of USD 0.81, below the USD 1.09 consensus cited by MarketBeat, while quarterly revenue reached USD 268.92 million against an expected USD 272.05 million.
Revenue still increased 12.3 percent year over year, supported by demand for WAKIX, Harmony's treatment for narcolepsy. The company maintained its full-year WAKIX revenue outlook of USD 1.0 billion to USD 1.04 billion, according to its November 4 release.
Pipeline remains a key focus
Harmony also reported preliminary multiple-ascending-dose results for BP-205, an investigational orexin-2 receptor agonist. The company expects Phase 1b results in the first quarter of 2027 and plans to begin Phase 2 studies across several central nervous system indications by mid-2027.
Rare-neurology specialist
Harmony Biosciences is a U.S. commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological disorders. Its lead product is WAKIX, while the company is expanding its pipeline in sleep disorders, epilepsy and other central nervous system conditions. Harmony is smaller and more specialized than diversified pharmaceutical groups such as Jazz Pharmaceuticals and UCB, while competing in narcolepsy with products and portfolios from companies including Avadel Pharmaceuticals.
Harmony Biosciences at a glance
- Company: Harmony Biosciences Holdings, Inc.
- ISIN: US4131971040
- Ticker: HRMY
- Primary listing: Nasdaq
- Sector: Pharmaceuticals and biotechnology
- Focus: Rare neurological disorders and central nervous system therapies
The S&P 500 market environment remains relevant for U.S. healthcare equities; see current S&P 500 market coverage.
